Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021.
- What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate stable heart failure (HF)? (0.31)
- Could you tell us a little about the RACE-3 study and its findings? (1.50)
- Among the interventions investigated in the study, which appeared to be most and least effective? (3.58)
- What follow-up studies are planned? (4.58)
- Following the results of this study, how do you envision the standard of care developing for patients with AF, with and without HF? (5.35)
Speaker disclosures: Prof. Michiel Rienstra wishes to disclose that RACE 3 was supported by the Netherlands Heart Foundation (Grant 2008B035), and the Netherlands Heart Institute. Further, this trial was funded by unrestricted grants from AstraZeneca, Bayer, Biotronik, Boehringer-Ingelheim, Boston Scientific, Medtronic, Sanofi-Aventis and St-Jude-Medical, paid to the Netherlands Heart Institute. Dr Bao-Oanh Nguyen has nothing to declare in relation to this video interview.
Interview and filming supported by Touch Medical Media. Interview conducted by Heather Hall.
Filmed during a remote video call with Prof. Michiel Rienstra and Dr Bao-Oanh Nguyen as a highlight of EHRA 2021, May 2021
Share this Video
Related Videos In Heart Failure
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
The BMAD trial investigated patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, findings and clinical implications of the BMAD trial in […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!